We are live on ! Find out more
NIP

Nicholas Investment Partners Portfolio holdings

AUM $1.39B
1-Year Est. Return 97.11%
This Fund
S&P 500
This Quarter Est. Return
+4.84%
1 Year Est. Return
+97.11%
3 Year Est. Return
+361.61%
5 Year Est. Return
+496.81%
10 Year Est. Return
+3,647.83%
AUM
$1.58B
AUM Growth
+$210M
Cap. Flow
+$71.1M
Cap. Flow %
4.5%
Top 10 Hldgs %
18.14%
Holding
221
New
32
Increased
92
Reduced
20
Closed
27

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$12.6M
2
PIII icon
P3 Health Partners
PIII
+$10.1M
3
MRVI icon
Maravai LifeSciences
MRVI
+$9.23M
4
NARI
Inari Medical, Inc. Common Stock
NARI
+$8.99M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$8.85M

Top Sells

Rank Stock Value
1
AMRS
Amyris Inc.
AMRS
+$13M
2
DMTK
DermTech, Inc. Common Stock
DMTK
+$12.9M
3
OSH
Oak Street Health, Inc.
OSH
+$11.8M
4
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$9.93M
5
DNA icon
Ginkgo Bioworks
DNA
+$8.89M

Sector Composition

Rank Sector Weight
1 Healthcare 30.22%
2 Technology 18.11%
3 Financials 10.26%
4 Industrials 8.95%
5 Consumer Discretionary 7.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PODD icon
26
Insulet
PODD
$9.79B
$16.7M 1.05%
62,588
+12,488
+25% +$3.62M
KTB icon
27
Kontoor Brands
KTB
$4.26B
$16.2M 1.02%
315,782
+41,658
+15% +$2.23M
BOOT icon
28
Boot Barn
BOOT
$4.95B
$15.9M 1.01%
129,114
+33,379
+35% +$3.77M
ASND icon
29
Ascendis Pharma A/S
ASND
$16.8B
$15.1M 0.95%
112,122
+84,988
+313% +$12.6M
MSFT icon
30
Microsoft
MSFT
$3.71T
$14.9M 0.94%
44,251
+25,161
+132% +$8.16M
CLAR icon
31
Clarus
CLAR
$143M
$14.7M 0.93%
529,907
+167,952
+46% +$4.64M
NEO icon
32
NeoGenomics
NEO
$2.13B
$14.6M 0.93%
428,378
+109,751
+34% +$4.3M
ARES icon
33
Ares Management
ARES
$30.9B
$14M 0.89%
172,100
+2,100
+1% +$171K
FRC
34
DELISTED
First Republic Bank
FRC
$13.9M 0.88%
67,358
– –
DNA icon
35
Ginkgo Bioworks
DNA
$521M
$13.6M 0.86%
40,825
-18,707
-31% -$8.89M
GS icon
36
Goldman Sachs
GS
$303B
$13.6M 0.86%
35,470
+470
+1% +$186K
BAC icon
37
Bank of America
BAC
$442B
$13.5M 0.86%
304,000
+4,000
+1% +$182K
KKR.PRC
38
DELISTED
KKR & Co. Inc. 6.00% Series C Mandatory Convertible Preferred Stock
KKR.PRC
– –
0
– –
KRYS icon
39
Krystal Biotech
KRYS
$9.66B
$13.4M 0.85%
191,311
-65,564
-26% -$3.82M
TKNO icon
40
Alpha Teknova
TKNO
$347M
$13.2M 0.84%
644,385
+39,615
+7% +$879K
JBTM
41
JBT Marel
JBTM
$6.39B
$13.2M 0.83%
85,907
+31,360
+57% +$4.91M
CVX icon
42
Chevron
CVX
$366B
$13.1M 0.83%
111,500
+1,500
+1% +$170K
XOM icon
43
ExxonMobil
XOM
$634B
$13M 0.82%
211,975
+1,975
+0.9% +$123K
TWST icon
44
Twist Bioscience
TWST
$7.25B
$12.8M 0.81%
165,051
+30,989
+23% +$3.18M
SHOO icon
45
Steven Madden
SHOO
$3.55B
$12.4M 0.78%
266,329
+23,769
+10% +$1.09M
SKIN icon
46
SkinHealth Systems
SKIN
$85.7M
$12.3M 0.78%
507,176
+111,682
+28% +$2.88M
TIL icon
47
Instil Bio
TIL
$50.3M
$12.2M 0.77%
35,661
+1,702
+5% +$657K
TEAM icon
48
Atlassian
TEAM
$37.8B
$11.4M 0.72%
29,965
+11,288
+60% +$4.54M
SLGC
49
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$11.4M 0.72%
980,806
+399,202
+69% +$4.78M
PACW
50
DELISTED
PacWest Bancorp
PACW
$11.2M 0.71%
248,503
+122,657
+97% +$5.72M
1
2
3 4 5

Similar funds

FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
OCM
Opti Capital Management New York $1.39B AUM 0% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
TA
Trivest Advisors Hong Kong $1.39B AUM 273.03% 1-Year Est. Return
AU
Algebris (UK) London, United Kingdom $1.38B AUM 3.87% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
BCP
Blue Chip Partners Farmington Hills, Michigan $1.39B AUM 22.32% 1-Year Est. Return

Nicholas Investment Partners's Q4 2021 Portfolio in Review

As of Q4 2021, Nicholas Investment Partners held 221 positions worth $1.58B, up 15% from $1.37B the previous quarter. Its ten largest holdings account for 18% of the portfolio.

Nicholas Investment Partners deployed $71.1M of net new capital in Q4 2021, opening 32 new positions and adding to 92 existing holdings. Its largest new stake was P3 Health Partners: 21,075 shares worth $7.42M.

By sector, the portfolio is most concentrated in Healthcare at 30% of assets, down from 36% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Ginkgo Bioworks, an estimated $8.89M trimmed.

  • Nicholas Investment Partners's largest Q4 2021 buy was P3 Health Partners: 21,075 shares worth $7.42M.
  • Nicholas Investment Partners added most to Ascendis Pharma A/S in Q4 2021, an estimated $12.6M increase.
  • Nicholas Investment Partners's biggest Q4 2021 reduction was Ginkgo Bioworks, cutting an estimated $8.89M.
  • Nicholas Investment Partners fully exited Amyris Inc. in Q4 2021, selling an estimated $13M.
  • Nicholas Investment Partners's ten largest holdings make up 18% of its $1.58B portfolio in Q4 2021.
  • Nicholas Investment Partners opened 32 new positions and closed 27 in Q4 2021.
  • Nicholas Investment Partners's portfolio value rose 15% quarter-over-quarter to $1.58B.

Based on Nicholas Investment Partners's 13F filing for Q4 2021, filed 14 Feb 2022.